Renewed U.S. generic-drug tariff threats hit the generics-and-bioprocess names — Amneal down 4%, Maravai down 4% — while the fill-finish chokepoint held and beaten-down Dr. Reddy's bounced.

Policy, not earnings, set the tone. Renewed concern over the U.S. plan to tariff imported generic drugs — a schedule that holds at zero for two years before stepping to 100% and later 200%, designed to force reshoring of generic manufacturing — pressured the names most exposed to offshore active-ingredient and finished-dose supply. Amneal was the vertical's laggard at −4.4% to $17.10, the clearest expression of the generics chokepoint in the basket and the most direct casualty of a tariff structure aimed squarely at imported finished doses. Maravai LifeSciences fell −4.3% to $5.81 at the nucleic-acid-and-bioprocess-inputs layer, extending weakness from its early-August print. The read is structural: the U.S. generic supply chain runs on Indian and Chinese API and dose manufacturing, and a tariff wall that eventually reaches triple digits is an existential re-rating of that dependency.

The leader was a bounce, not a tariff winner. Dr. Reddy's rose +2.5% to $12.45 — notable precisely because, as an India-based generics-and-specialty ADR, it is among the names the tariff plan targets. After a steep slide driven by that same tariff overhang and a soft recent quarter, the move read as an oversold technical bid rather than a change in the fundamental setup; the structural pressure on offshore generics has not eased. It was the largest clean gainer in the vertical, but the more thesis-consistent strength sat one tier up the supply chain, in the domestic-leaning primary-packaging and services names insulated from finished-dose tariffs.

That fill-finish-and-CDMO chokepoint held up on the day. Stevanato added +2.3% to $21.05 at the glass-and-injectable-primary-packaging choke, and Charles River +1.8% to $282.00 in preclinical-and-CDMO services — the capacity bottleneck that gates every biologic and GLP-1 launch, and a domestic-footprint story less exposed to import duties. The analytical-instruments layer that gates QC firmed modestly (Thermo Fisher +0.9% to $605.00, Waters +0.8% to $415.00, Agilent +0.5%), while the GLP-1 majors were soft — Eli Lilly −1.4% to $1,215.02 and Novo Nordisk −1.2% to $47.17 — keeping the day's weakness anchored in the tariff-sensitive corners rather than the broad market.

The near-term calendar leans toward the packaging-and-services chokepoint that outperformed today: SCHOTT Pharma posts its fiscal-Q3 quarterly statement today at the pharma-glass choke, and Hikma's H1 interim results are expected around August 13 on the generics-and-injectables side most levered to the tariff debate. Agilent's fiscal-Q3 print lands August 26 at the QC-instruments layer, and CPHI Worldwide — the industry's supply-chain and CDMO gathering — convenes in Milan October 6–8, where reshoring economics under the new tariff regime will be the central conversation. Watch whether the domestic fill-finish names keep their premium as the generic-tariff timeline sharpens.